Corient Private Wealth
STAB

Corient Private Wealth’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Corient Private Wealth’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-43,350
Closed -$3.52K – 2076
2022
Q4 		$3.52K Buy
+43,350
New +$5.5K ﹤0.01% 1689

Other funds holding STAB

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TAM
Tucker Asset Management Littleton, Colorado $343M AUM 17.55% 1-Year Est. Return

Corient Private Wealth's STAB Position: Q1 2023 in Review

Corient Private Wealth sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 43,350 shares — an estimated $3.52K sold.

Corient Private Wealth first reported a position in STAB in Q4 2022 and held it in 1 quarter. The position peaked at $3.52K in Q4 2022. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.

  • Corient Private Wealth reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Corient Private Wealth sold 43,350 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $3.52K.
  • Corient Private Wealth first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Corient Private Wealth's Statera Biopharma, Inc. Common Stock position peaked at $3.52K in Q4 2022.
  • 4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.

Based on Corient Private Wealth's 13F filing for Q1 2023, filed 15 May 2023.